Quantum Cyber N.V. annual report, Q4 FY2021

Business context and reporting period

This is Mainz Biomed N.V.’s annual report on Form 20-F for the fiscal year ended December 31, 2021, prepared under IFRS as issued by the IASB. It is not a standalone fourth-quarter report. The request metadata names Quantum Cyber N.V.; that does not match the registrant identified in the filing, which is Mainz Biomed N.V. The company develops and sells molecular diagnostic tests, led by its European colorectal cancer screening test, ColoAlert.

In September 2021, Mainz Biomed acquired PharmGenomics GmbH in a share exchange. For accounting purposes, the transaction was treated as a reverse acquisition, with PharmGenomics as the accounting acquirer. The ordinary shares began trading on Nasdaq in November 2021.

Financial performance and position

MetricFY 2021FY 2020
Revenue$577,348$493,565
Gross profit$177,622$123,085
Gross margin31%25%
Operating expenses$9,902,228$796,800
Operating loss$(9,724,606)$(673,715)
Net loss$(11,690,098)$(586,895)
Net cash used in operating activities$(3,220,324)$(468,737)
Cash and cash equivalents at year-end$8,727,542$122,568

Revenue grew 17%. ColoAlert revenue was $226,438, up from $167,074; third-party laboratory testing and support generated $233,662, including COVID-19-related work that management expected to decrease after 2021. Gross margin improved to 31% from 25%, while the company remained substantially loss-making. Loss per ordinary share was $1.62, compared with $0.10 in 2020.

The sharp increase in expenses included $6.43 million of stock-based compensation in general and administrative expenses, higher sales and marketing spending, and $2.02 million of acquisition expense recorded outside operating expenses. The company reported $298,997 of research and development grants in 2021.

At December 31, 2021, total assets were $10.04 million, total liabilities were $3.68 million, and shareholders’ equity was $6.36 million. Current assets were $9.61 million against current liabilities of $1.35 million. Total lease liabilities were $442,842. Silent partnership liabilities were $1.94 million, including related-party balances; these are debt-like funding arrangements with interest and, in some cases, additional maturity payments or profit participation.

Net cash provided by financing activities was $10.61 million, principally reflecting the November 2021 IPO, which generated approximately $10.43 million net proceeds. The company reported $1.20 million of net cash provided by investing activities in the audited cash flow statement, primarily from cash acquired in the reverse acquisition. Management said the January 2022 follow-on offering raised $23.53 million net proceeds and that approximately $29 million from the two offerings remained as of the report date.

Material changes versus the prior comparable period

  • Revenue increased 17%, led by ColoAlert and laboratory testing activity; gross margin rose six percentage points.
  • Operating expenses increased more than twelvefold, primarily due to IPO-related stock-option compensation, merger-related professional costs, hiring, and increased advertising and sales activity.
  • Net loss widened to $11.69 million from $586,895, with the acquisition expense and non-cash stock compensation among the major unusual items.
  • Year-end cash rose to $8.73 million from $122,568 following the IPO and acquisition. Operating cash use also increased materially.
  • The company issued 2.3 million shares in its November 2021 IPO and reported 12,010,000 ordinary shares outstanding at period-end on the cover page.

Outlook, commentary, risks and contingencies

Management stated that cash on hand, together with the January 2022 offering proceeds, was expected to fund planned operating requirements for the next twelve months. This is not a profitability forecast: the company disclosed recurring losses, an accumulated deficit of $16.64 million, and negative operating cash flow. The financial statements were prepared on a going-concern basis.

Management’s strategy is to expand ColoAlert through laboratory partners in Europe, prepare clinical and regulatory studies for U.S. market authorization, and continue research and development. FDA authorization would require extensive studies, with timing and success uncertain. PancAlert remained at an early research stage, with pilot studies not expected to conclude before 2024 at the earliest; GenoStrip was also early-stage and could be discontinued. A January 2022 option to license University of Sherbrooke biomarkers for ColoAlert is contingent on further study results and could entail future royalties and patent costs.

  • Commercial and concentration risks: ColoAlert is the principal prospective growth driver; physician and patient adoption, laboratory partnerships, reimbursement, competitive tests, and brand awareness are uncertain. Four customers accounted for approximately 56% of 2021 revenue.
  • Regulatory and product risks: The company must address stricter EU IVD Regulation requirements and pursue FDA authorization for U.S. screening claims. Clinical performance, approval timing, and additional study requirements are uncertain.
  • Intellectual property: The filing states that the company had no patents or pending patent applications at the report date and relied substantially on licensed rights, trade secrets, and know-how.
  • Financing and dilution: Management expected future financing could include equity, debt, or preferred shares. Further issuance could dilute existing shareholders. The company does not expect to pay dividends in the foreseeable future.
  • Debt and contractual obligations: Silent partnership arrangements include minimum interest and potential additional payments at maturity. Disclosed maturities include obligations in 2023 and 2025, alongside lease commitments.
  • Other risks: The filing cites foreign-exchange exposure, COVID-19 and broader economic uncertainty, data privacy and healthcare compliance, product liability, and the challenges of integrating the acquired business.

The auditor issued an unqualified opinion on the IFRS financial statements. Management concluded that disclosure controls and internal control over financial reporting were effective at year-end; the auditor was not engaged to provide an internal-control attestation.

Most important facts an investor should verify

  1. Confirm the issuer identity: the filing is for Mainz Biomed N.V., not Quantum Cyber N.V., and covers FY 2021 rather than Q4 alone.
  2. Reconcile reported cash-flow figures: the MD&A table gives investing cash flow of $1,230,151, while the audited cash flow statement reports $1,203,151.
  3. Verify the period-end share count and subsequent dilution from the January 2022 offering, warrant exercises, outstanding warrants, and options.
  4. Assess cash runway using updated operating cash burn, remaining offering proceeds, and upcoming silent partnership and lease payments.
  5. Track ColoAlert sales, customer concentration, reimbursement progress, EU IVD-R compliance, and the scope, cost, and timeline of FDA studies.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.